Interestingly, after gefitinib treatment, the percentage of metaphase cells of tumours derived from GOLPH3 over‐expression group decreased by 71.17%, which was more striking than that of the control group (21.52% decrease, Figure 5D), indicating that over‐expression of GOLPH3 enhanced the anti‐tumour effect of gefitinib in vivo. Here, GOLPH3 is linked to neoplasm.